Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches

References

• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. doi: 10.4088/JCP.13r08440
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–619. doi: 10.1093/schbul/sbx090
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. doi: 10.1176/appi.ajp.2011.10081224
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical Trial. JAMA Psychiatry. 2020;77(12):1217–1224. doi: 10.1001/jamapsychiatry.2020.2076
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8(5):387–404. doi: 10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. doi: 10.1002/wps.20994
   PubMed Web of Science ®Google Scholar
• Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230. doi: 10.1016/j.schres.2016.07.018
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment. Expert Opin Pharmacother. 2019;20(1):11–24. doi: 10.1080/14656566.2018.1543409
   PubMed Web of Science ®Google Scholar
• Verdoux H, Pambrun E, Tournier M, et al. Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophr Res. 2016;178(1–3):58–63. doi: 10.1016/j.schres.2016.09.014
   PubMed Web of Science ®Google Scholar
• Arango C, Baeza I, Bernardo M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment. 2019;12(2):92–105. doi: 10.1016/j.rpsm.2018.03.006
   PubMed Web of Science ®Google Scholar
• Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010;11(14):2301–2317. doi: 10.1517/14656566.2010.499125
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24. doi: 10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Ross R, Legacy SN, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018;14:1463–1474. doi: 10.2147/NDT.S167394
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Ross R, Legacy SN, et al. Initiating/Maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018;14:1475–1492 doi: 10.2147/NDT.S167485
   PubMed Web of Science ®Google Scholar
• Kane JM, McEvoy JP, Correll CU, et al. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189–1205. doi: 10.1007/s40263-021-00861-6
   PubMed Web of Science ®Google Scholar
• Correll CU. Addressing barriers to using long-acting injectable antipsychotics and appropriately monitoring antipsychotic adverse effects. J Clin Psychiatry. 2013;74(8):e16. doi: 10.4088/JCP.12117tx3c
   Google Scholar
• Correll CU. The role of the extended health care team in successful LAI therapy: education to overcome barriers. J Clin Psychiatry. 2014;75(9):e25. doi: 10.4088/JCP.13024tx4c
   PubMedGoogle Scholar
• Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684–690. doi: 10.4088/JCP.13m08946
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the prelapse trial. J Clin Psychiatry. 2019;80(3):18m12546. doi: 10.4088/JCP.18m12546
   PubMed Web of Science ®Google Scholar
• Fiorillo A, Barlati S, Bellomo A, et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Ann Gen Psychiatry. 2020;19(1):43. doi: 10.1186/s12991-020-00293-4
   PubMed Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(S2):S12–S21. doi: 10.1016/S0924-9338(10)71701-6
   PubMedGoogle Scholar
• Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69:4–17
   Web of Science ®Google Scholar
• Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67(1):160–161. doi: 10.4088/JCP.v67n0122
   PubMed Web of Science ®Google Scholar
• Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet. 1985;10(4):315–333. doi: 10.2165/00003088-198510040-00003
   PubMed Web of Science ®Google Scholar
• Meyer JM. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr. 2013;18 Suppl 1(s1):55–68. doi: 10.1017/S1092852913000783
   Google Scholar
• Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. doi: 10.1007/s40263-020-00779-5
   PubMed Web of Science ®Google Scholar
• Stahl SM, Grady MM. Stahl’s essential psychopharmacology: prescriber’s guide. Sixth ed. Cambridge: (UK) ; New York: Cambridge University Press; 2017.
   Google Scholar
• Lundbeck Canada Inc. Fluanxol Depot (flupenthixol decanoate) [product monograph] [Internet]. [cited 2022 Apr 23]. Available from: https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/fluanxol_product_monograph_english.pdf.
   Google Scholar
• APP Pharmaceuticals. Fluphenazine decanoate [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/071413s019lbl.pdf.
   Google Scholar
• Janssen Pharmaceuticals Companies. Haldol Decanoate (haloperidol decanoate) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/HALDOL+Decanoate-pi.pdf.
   Google Scholar
• European Medicines Agency. Summary of product characteristics: haldol and associated names (haloperidol) [Internet]. [cited 2021 Dec 20]. Available from: https://www.ema.europa.eu/en/documents/referral/haldol-article-30-referral-annex-iii_en.pdf.
   Google Scholar
• Orion Pharma. Perphenazine decanoate [summary of product characteristics [Internet]. [cited 2022 Apr 23]. Available from: www.produktresume.dk.
   Google Scholar
• Lundbeck Canada Inc. Clopixol Depot (zuclopenthixol decanoate) [product monograph] [Internet]. [cited 2022 Apr 23]. Available from: https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf.
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd. Abilify Maintena (aripiprazole monohydrate) [US prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https://www.otsuka-us.com/media/static/Abilify-M-PI.pdf?_ga=2.37700576.1548399021.1559037290-53464514.1559037290.
   Google Scholar
• European Medicines Agency. Abilify Maintena (aripirazole monohydrate) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena.
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd. Abilify Asimtufii (aripiprazole monohydrate) [ US prescribing information].
   Google Scholar
• Alkermes, Inc. Aristada (aripirazole luaroxil) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https://www.aristada.com/downloadables/ARISTADA-PI.pdf.
   Google Scholar
• Alkermes, Inc. Aristada Initio (aripiprazole luaroxil) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https://www.aristada.com/downloadables/ARISTADA-INITIO-PI.pdf.
   Google Scholar
• Lilly USA, LLC. Zyprexa Relprevv - Prescribing information [Internet]. [cited 2022 Apr 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022173s015lbl.pdf.
   Google Scholar
• European Medicines Agency. Zypadhera (olanzapine pamoate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/zypadhera-epar-product-information_en.pdf.
   Google Scholar
• Janssen Pharmaceuticals Companies. Invega Sustenna (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf.
   Google Scholar
• European Medicines Agency. Xeplion (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/xeplion-epar-product-information_en.pdf.
   Google Scholar
• Janssen Pharmaceuticals Companies. Invega Trinza (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf.
   Google Scholar
• European Medicines Agency. Trevicta (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/trevicta-epar-product-information_en.pdf.
   Google Scholar
• Janssen Pharmaceuticals. Invega Hafyera (paliperidone palmitate) [prescribing information] [Internet]. [cited 2022 Apr 20]. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+HAFYERA-pi.pdf.
   Google Scholar
• European Medicines Agency. Byannli (paliperidone palmitate) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/byannli-previously-paliperidone-janssen-cilag-international-epar-product-information_en.pdf.
   Google Scholar
• Janssen Pharmaceuticals. Risperdal Consta (risperidone microspheres) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RISPERDAL+CONSTA-pi.pdf.
   Google Scholar
• Shandong Luye Pharmaceutical Co., Ltd. Rykindo (risperidone) for extended-release injectable suspension for intramuscular use [prescribing information] [Internet]. [cited 2023 May 2]. Available from: https://www.luye.cn/lvye_en/rykindo.pdf.
   Google Scholar
• Indivior Inc. Perseris (risperidone) [prescribing information] [Internet]. [cited 2022 Apr 23]. Available from: https://www.perserishcp.com/prescribing-information.pdf.
   Google Scholar
• European Medicines Agency. Okedi (subcutaneous risperidone) [summary of product characteristics] [Internet]. [cited 2022 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/okedi-epar-product-information_en.pdf.
   Google Scholar
• Teva Neuroscience Inc. Uzedy (risperidone) extended-release injectable suspension for subcutaneous use [prescribing information] [Internet]. [cited 2023 Apr 29]. Available from: https://www.uzedy.com/globalassets/uzedy/prescribing-information.pdf.
   Google Scholar
• Raoufinia A, Peters-Strickland T, Nylander A-G, et al. Aripiprazole Once-Monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017;20(4):295–304. doi: 10.1093/ijnp/pyw116
   PubMed Web of Science ®Google Scholar
• Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52(S52):S13–19. doi: 10.1192/bjp.195.52.s13
   PubMedGoogle Scholar
• Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13(7):767–783. doi: 10.1586/14737175.2013.811984
   PubMed Web of Science ®Google Scholar
• Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken: NJ: Wiley; 2019.
   Google Scholar
• Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–340. doi: 10.1002/wps.20579
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical application. 4th ed. Cambridge, United Kingdom: Cambridge University Press; 2013.
   Google Scholar
• Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther. 2004;26(12):1994–2002. doi: 10.1016/j.clinthera.2004.12.009
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(Suppl 16):18–23.
   PubMed Web of Science ®Google Scholar
• Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr. 2017;22(S1):14–28. doi: 10.1017/S1092852917000840
   PubMedGoogle Scholar
• Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169–186. doi: 10.1586/17512433.2016.1121809
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085–1090. doi: 10.4088/JCP.14m09741
   PubMed Web of Science ®Google Scholar
• Raoufinia A, Baker RA, Eramo A, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin. 2015;31(3):583–592. doi: 10.1185/03007995.2015.1006356
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–288. doi: 10.1016/j.schres.2013.06.041
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Harlin M, et al. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Curr Med Res Opin. 2021;37(11):1961–1972. doi: 10.1080/03007995.2021.1965974
   PubMed Web of Science ®Google Scholar
• Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2021;26(2):118–129. doi: 10.1017/S1092852921000249
   Web of Science ®Google Scholar
• Hard ML, Mills RJ, Sadler BM, et al. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289–295. doi: 10.1097/JCP.0000000000000691
   PubMed Web of Science ®Google Scholar
• Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Rev Neurother. 2017;17(10):1029–1043. doi: 10.1080/14737175.2017.1371014
   PubMed Web of Science ®Google Scholar
• Jain R, Meyer J, Wehr A, et al. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectr. 2020;25(3):323–330. doi: 10.1017/S1092852919000816
   PubMed Web of Science ®Google Scholar
• Hard ML, Mills RJ, Sadler BM, et al. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase i study and a population pharmacokinetic model. CNS Drugs. 2017;31(7):617–624. doi: 10.1007/s40263-017-0447-7
   PubMed Web of Science ®Google Scholar
• Hard ML, Wehr AY, Du Y, et al. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. J Clin Psychopharmacol. 2018;38(5):435–441. doi: 10.1097/JCP.0000000000000921
   PubMed Web of Science ®Google Scholar
• Hard ML, Wehr AY, Sadler BM, et al. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet. 2018;43(4):461–469. doi: 10.1007/s13318-018-0488-4
   PubMed Web of Science ®Google Scholar
• Heres S, Kraemer S, Bergstrom RF, et al. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol. 2014;29(6):299–312. doi: 10.1097/YIC.0000000000000040
   PubMed Web of Science ®Google Scholar
• Meyers KJ, Upadhyaya HP, Landry JL, et al. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. BJPsych Open. 2017;3(4):186–192. doi: 10.1192/bjpo.bp.116.004382
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010;10(1):45. doi: 10.1186/1471-244X-10-45
   PubMedGoogle Scholar
• Bioque M, Bernardo M. The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opin Pharmacother. 2018;19(14):1623–1629. doi: 10.1080/14656566.2018.1515915
   PubMed Web of Science ®Google Scholar
• Rossenu S, Cleton A, Hough D, et al. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Clin Pharmacol Drug Dev. 2015;4(4):270–278. doi: 10.1002/cpdd.144
   PubMed Web of Science ®Google Scholar
• Carabias L, Llaudó J, Ayani I, et al. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2018;33(2):79–87. doi: 10.1097/YIC.0000000000000203
   PubMed Web of Science ®Google Scholar
• Gomeni R, Heidbreder C, Fudala PJ, et al. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. J Clin Pharmacol. 2013;53(10):1010–1019. doi: 10.1002/jcph.141
   PubMed Web of Science ®Google Scholar
• Citrome L. Sustained- release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERIS™) for the Treatment of Schizophrenia. Clin Schizophr Relat Psychoses. 2018;12(3):130–141. doi: 10.3371/CSRP.CI.101118
   PubMedGoogle Scholar
• Schoretsanitis G, Kane JM, Correll CU, et al. Predictors of lack of relapse after random discontinuation of oral and long-acting injectable antipsychotics in clinically stabilized patients with schizophrenia: a re-analysis of individual participant data. Schizophr Bull. 2022;48(2):296–306. doi: 10.1093/schbul/sbab091
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Straub L, Karlsson P, et al. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic Countries and the US. JAMA Psychiatry. 2023;80(2):156–166. doi: 10.1001/jamapsychiatry.2022.4109
   PubMed Web of Science ®Google Scholar
• Højlund M, Kemp AF, Haddad PM, et al. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry. 2021;8(6):471–486. doi: 10.1016/S2215-0366(21)00078-X
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry. 2022;9(8):614–624. doi: 10.1016/S2215-0366(22)00158-4
   PubMed Web of Science ®Google Scholar
• Lähteenvuo M, Luykx JJ, Taipale H, et al. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. Br J Psychiatry. 2022;221(6):758–765. doi: 10.1192/bjp.2022.117
   PubMed Web of Science ®Google Scholar
• Rubio JM, Taipale H, Correll CU, et al. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol Med. 2020;50(8):1356–1367. doi: 10.1017/S0033291719001296
   PubMed Web of Science ®Google Scholar
• Emsley R, Asmal L, Rubio JM, et al. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res. 2020;225:55–62. doi 10.1016/j.schres.2019.11.025
   PubMed Web of Science ®Google Scholar
• Rubio JM, Schoretsanitis G, John M, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7(9):749–761. doi: 10.1016/S2215-0366(20)30264-9
   PubMed Web of Science ®Google Scholar
• Correll CU, Sliwa JK, Najarian DM, et al. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectr. 2019;24(4):354–370. doi: 10.1017/S1092852918001098.
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry Off J World Psychiatr Assoc WPA. 2013;12(3):216–226. doi: 10.1002/wps.20060
   PubMed Web of Science ®Google Scholar
• Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69. doi: 10.1017/S109285291900124X
   PubMedGoogle Scholar
• Kane JM, Harary E, Tohami O, et al. Subcutaneous risperidone (TV-46000) efficacy and safety in schizophrenia: a phase 3, randomized, double-blind, relapse prevention study (RISE Study). Florence: Italy; 2022.
   Google Scholar
• Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023;22(1):48–74. doi: 10.1002/wps.21056
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Co., Ltd. NCT05119894: a multicenter, open-label, clinical pharmacology trial to determine the pharmacokinetics, tolerability, and safety of brexpiprazole Long Acting Injectable (LAI) administered as a single dose in patients with schizophrenia [Internet]. 2021 [cited 2022 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT05119894.
   Google Scholar
• Intra-Cellular Therapies, Inc. NCT04709224: an Open-label Study to Determine the Pharmacokinetics, Safety and Tolerability of Single Ascending Doses of a Subcutaneous Injection of Lumateperone Long-Acting Injectable (LAI) Formulation in Patients with Schizophrenia [Internet]. 2022 [cited 2022 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04709224.
   Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. doi: 10.1001/jamapsychiatry.2017.1322
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Lu PH, Raven EP, et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res. 2012;140(1–3):122–128. doi: 10.1016/j.schres.2012.06.036
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Triple advantages of injectable long acting second generation antipsychotics: relapse prevention, neuroprotection, and lower mortality. Schizophr Res. 2018;197:69–70. doi: 10.1016/j.schres.2018.02.004
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat. 2018;14:2563–2577. doi: 10.2147/NDT.S159704
   PubMed Web of Science ®Google Scholar
• Correll CU, Jain R, Meyer JM, et al. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat. 2019;15:2537–2550. doi: 10.2147/NDT.S210340
   PubMed Web of Science ®Google Scholar
• Nandhra HS, Sule A. Oral depot antipsychotic drugs: time for a paradigm shift? J Ment Health Abingdon Engl. 2015;24(4):181–182. doi: 10.3109/09638237.2014.973102
   PubMed Web of Science ®Google Scholar
• Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophr Heidelb Ger. 2022;8(1):5. doi: 10.1038/s41537-021-00192-x
   PubMedGoogle Scholar